Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Expenses (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Accumulated Expenses for 16 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 22.34% to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.8 million through Dec 2025, up 22.34% year-over-year, with the annual reading at $16.8 million for FY2025, 22.34% up from the prior year.
  • Accumulated Expenses hit $16.8 million in Q4 2025 for Ani Pharmaceuticals, up from $14.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $29.8 million in Q3 2024 to a low of $3.3 million in Q1 2022.
  • Historically, Accumulated Expenses has averaged $11.4 million across 5 years, with a median of $10.1 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: surged 222.13% in 2024 and later plummeted 53.15% in 2025.
  • Year by year, Accumulated Expenses stood at $7.6 million in 2021, then soared by 34.8% to $10.3 million in 2022, then tumbled by 45.64% to $5.6 million in 2023, then skyrocketed by 145.01% to $13.7 million in 2024, then grew by 22.34% to $16.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for ANIP at $16.8 million in Q4 2025, $14.0 million in Q3 2025, and $14.8 million in Q2 2025.